Abstract: EUSOBI and 30 national breast radiology bodies support mammography for population-based screening, demonstrated to reduce breast cancer BC mortality and treatment impact. According to the International Agency for Research on Cancer, the reduction in mortality is 40nbsp;% for women aged 50ndash;69nbsp;years taking up the invitation while the probability of false-positive needle biopsy is 1nbsp;% per round and overdiagnosis is only 1ndash;10nbsp;% for a 20-year screening. Mortality reduction was also observed for the age groups 40ndash;49nbsp;years and 70ndash;74nbsp;years, although with ldquo;limited evidencerdquo;. Thus, we firstly recommend biennial screening mammography for average-risk women aged 50ndash;69nbsp;years; extension up to 73 or 75nbsp;years, biennially, is a second priority, from 40ndash;45 to 49nbsp;years, annually, a third priority. Screening with thermography or other optical tools as alternatives to mammography is discouraged. Preference should be given to population screening programmes on a territorial basis, with double reading. Adoption of digital mammography not film-screen or phosphor-plate computer radiography is a priority, which also improves sensitivity in dense breasts. Radiologists qualified as screening readers should be involved in programmes. Digital breast tomosynthesis is also set to become ldquo;routine mammographyrdquo; in the screening setting in the next future. Dedicated pathways for high-risk women offering breast MRI according to national or international guidelines and recommendations are encouraged. Key points: bull; EUSOBI and 30 national breast radiology bodies support screening mammography. bull; A first priority is double-reading biennial mammography for women aged 50ndash;69nbsp;years. bull; Extension to 73ndash;75 and from 40ndash;45 to 49nbsp;years is also encouraged. bull; Digital mammography not film-screen or computer radiography should be used. bull; DBT is set to become ldquo;routine mammographyrdquo; in the screening setting in the next future.